Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03918408 · ClinicalTrials.gov registry record · Phase 1
Safety and Effectiveness of the PXL-Platinum 330 System for Corneal Cross-Linking
A Phase 1 study of Keratoconus, Unstable and Bacterial Keratitis, sponsored by Pacific Clear Vision Institute.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 300
- Enrollment target
- 1
- Study location
NCT03918408: Recruiting Phase 1 study of Keratoconus, Unstable and Bacterial Keratitis, sponsored by Pacific Clear Vision Institute.
NCT03918408 is a Phase 1 study of Keratoconus, Unstable and Bacterial Keratitis that is actively recruiting participants, run by Pacific Clear Vision Institute. The registered enrollment target is 300 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (400% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03918408, a Phase 1 study of Keratoconus, Unstable and Bacterial Keratitis, is actively recruiting participants, sponsored by Pacific Clear Vision Institute.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 300 participants
- Enrollment target
- 1
- Study location
Study Summary
To determine whether the Peschke PXL-330 system is safe and effective in the treatment of corneal thinning conditions.
Primary Outcome
Average keratometry across the anterior topography of the cornea computed by a validated Scheimpflug topographer
Conditions Studied
Interventions
- COMBINATION_PRODUCT PXL-330 Platinum device for crosslinking with Peschke ribofflavin solution
Study Locations (1)
Oregon
- Pacific Clear Vision Institute - Eugene
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2019-09-01 |
| Est. Completion | 2030-12 |
| Phase | Phase 1 |
What NCT03918408 shows while recruiting
NCT03918408 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (400% higher).
The record links to 3 conditions, with Keratoconus, Unstable appearing as the primary indexed condition, and to 1 intervention - of which PXL-330 Platinum device for crosslinking with Peschke ribofflavin solution is the first listed.
NCT03918408 reports a single indexed study location in Oregon.
Frequently Asked Questions
What is clinical trial NCT03918408 about?
NCT03918408 is a clinical study titled "Safety and Effectiveness of the PXL-Platinum 330 System for Corneal Cross-Linking". To determine whether the Peschke PXL-330 system is safe and effective in the treatment of corneal thinning conditions.
What is the current status of trial NCT03918408?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 300 participants. The study started on 2019-09-01. Estimated completion is 2030-12.
What conditions does trial NCT03918408 study?
This clinical trial studies the following conditions: Keratoconus, Unstable, Bacterial Keratitis, Ectasia of Cornea.
What interventions are being tested in trial NCT03918408?
The interventions under investigation include: PXL-330 Platinum device for crosslinking with Peschke ribofflavin solution (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT03918408?
This trial is sponsored by Pacific Clear Vision Institute, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03918408 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Keratoconus, Unstable
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03918408's enrollment target sits among peer trials
300 124th of 2000 higher than 1,867 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI